1 North Waukegan Road
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
1158 articles with AbbVie
AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis
New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis
AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ™ (upadacitinib) and HUMIRA® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9.
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis
AbbVie (NYSE: ABBV) today announced that it has submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ™ (upadacitinib) for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate to severe atopic dermatitis.
("AbbVie") announced today the commencement of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019 (the " 2019 USD Notes"), (ii) $13,251,781,000 aggregate principal amount
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older,
AbbVie (NYSE: ABBV) will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens.
10/6/2020According to BioSpace research, 69% of biotech professionals feel they are on the verge of job burnout. Do you fall into that 69%? Is it time for a new job? Check out the top companies who are looking for candidates like you right now!
AbbVie to Present New Data From 15 Abstracts at the 2020 Virtual Migraine Trust International Symposium
- New data from Phase 3 ADVANCE trial evaluating investigational medicine atogepant for the preventive treatment of migraine accepted for oral presentation - Presentation of real-world evidence assessing safety, tolerability, and potential benefits of treatment with BOTOX® (onabotulinumtoxinA) in combination with calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for chronic migraine prevention - Oral presentation of Phase 3 data measuring the efficacy and sa
Allergan Aesthetics, an AbbVie company, announced the launch of SkinMedica® TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™ treatments.
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury
- Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury - Orphan Drug Designation is given to a drug or biologic for the treatment, diagnosis or prevention of a rare disease or condition¹ - Fast Track Designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs²
Voting for the 2020 AbbVie CF Scholarship Thriving Student Awards is Open to the Public Until September 30
- Forty students received $3,000 scholarships earlier this year based on their academic excellence, creativity, and community involvement/extracurricular activities - The public is now invited to cast their votes to help determine this year's Thriving Scholars - Scholarships totaling $25,000 each - the Thriving Undergraduate Scholarship and the Thriving Graduate Scholarship - will be awarded to two deserving students
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.18 per share.
AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®
AbbVie (NYSE: ABBV) today announced it will present results from several studies, including the DYSCOVER study evaluating the efficacy of DUODOPA® (levodopa/carbidopa intestinal gel) on the duration and severity of dyskinesia in patients with advanced Parkinson's disease (PD), at the 2020 International Congress of Parkinson's Disease and Movement Disorders® Virtual Congress, September 12-16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)
AbbVie and I-Mab announced today that they had entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4). The anti-CD47 monoclonal antibody was initially discovered and developed by I-Mab for the treatment of various cancers.
AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020.
Shares of AbbVie fell nearly 4% Tuesday following the issuance of a subpoena from the U.S. House Oversight and Reform Committee regarding an ongoing investigation into drug pricing.
'Say No to Chronic Migraine Monday' Urges People Living with Chronic Migraine to Seek Help from a Headache Specialist
Each Monday throughout Pain Awareness Month, online influencers share motivations for finding a headache specialist to discuss treatment options
AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis
- RINVOQ demonstrated significant improvements to signs and symptoms of active ankylosing spondylitis - In a pivotal Phase 2/3 study, twice as many patients receiving RINVOQ achieved the primary endpoint of ASAS 40 response at week 14 compared to placebo (p<0.001) - A regulatory application was also submitted to the EMA for the treatment of adult patients with active ankylosing spondylitis earlier this year - This submission represents AbbVie's ongoing comm